Germline CDH1 Variants and Lifetime Cancer Risk
JAMA Network
American Association for the Advancement of Science (AAAS)
June 2024
Dr. Jeremy Davis co-authored a JAMA study revealing that individuals with germline CDH1 mutations have a lower lifetime risk of gastric cancer than previously estimated. This finding may influence clinical decisions regarding preventive surgeries. Dr. Davis emphasized the significance of collaborative research in understanding this rare condition.
Removing Risk of Stomach Cancer for her Daughter
Center for Cancer Research
NIH: National Cancer Institute
November 2022
Dr. Jeremy Davis is featured in a story from the National Cancer Institute about a young mother who underwent preventive surgery after learning she carried a rare genetic mutation that significantly increased her risk for stomach cancer. As part of an NIH research program, Dr. Davis performed the life-changing surgery to remove her stomach and eliminate the threat of cancer.